Intermittent hormone therapy for prostate cancer

Published: February, 2008

Editor in Chief Marc B. Garnick, M.D., discusses this therapy, which aims to strike a balance between effective treatment and quality of life

Androgens, the family of male sex hormones that includes testosterone, trigger sexual development, the growth of facial hair, a deepening voice, and increased muscle and bone mass. But when prostate cancer begins to develop, androgens seemingly turn traitor by fueling tumor growth. In the 1940s, Dr. Charles Huggins, a researcher at the University of Chicago, demonstrated in Nobel Prize""winning experiments that shutting down androgen production could rein in prostate cancer. Since then, androgen deprivation, commonly called hormone therapy, has been the mainstay of treatment for metastatic prostate cancer.

To continue reading this article, you must log in.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise

New subscriptions to Harvard Health Online are temporarily unavailable. Click the button below to learn about our other subscription offers.

Learn More »